Nextage Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2021: 2.32%

Nextage Therapeutics Ltd (NXTG) has an Asset Resilience Ratio of 2.32% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Nextage Therapeutics Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

ILA99.00K

≈ $265.42 USD Cash + Short-term Investments

Total Assets

ILA4.27 Million

≈ $11.45K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2021)

This chart shows how Nextage Therapeutics Ltd's Asset Resilience Ratio has changed over time. See net assets of Nextage Therapeutics Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Nextage Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nextage Therapeutics Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA99.00K	2.32%
Total Liquid Assets	ILA99.00K	2.32%

Asset Resilience Insights

Limited Liquidity: Nextage Therapeutics Ltd maintains only 2.32% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Nextage Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Nextage Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd SHG:600276	Drug Manufacturers - Specialty & Generic	0.16%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Henan Newland Pharmaceutical Co. Ltd. A SHE:301277	Drug Manufacturers - Specialty & Generic	31.63%
Hainan Shuangcheng Pharmaceut SHE:002693	Drug Manufacturers - Specialty & Generic	3.29%

Annual Asset Resilience Ratio for Nextage Therapeutics Ltd (2017–2021)

The table below shows the annual Asset Resilience Ratio data for Nextage Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	2.32%	ILA99.00K ≈ $265.42	ILA4.27 Million ≈ $11.45K	+1.46pp
2020-12-31	0.86%	ILA35.00K ≈ $93.83	ILA4.07 Million ≈ $10.91K	-1.17pp
2019-12-31	2.03%	ILA122.00K ≈ $327.08	ILA6.01 Million ≈ $16.10K	-0.20pp
2018-12-31	2.23%	ILA122.00K ≈ $327.08	ILA5.48 Million ≈ $14.68K	+1.24pp
2017-12-31	0.98%	ILA122.00K ≈ $327.08	ILA12.39 Million ≈ $33.23K	--

pp = percentage points

About Nextage Therapeutics Ltd

TA:NXTG Israel Drug Manufacturers - Specialty & Generic

Market Cap

$5.79 Million

ILA2.16 Billion ILA

Market Cap Rank

#28074 Global

#409 in Israel

Share Price

ILA64.10

Change (1 day)

-17.72%

52-Week Range

ILA64.10 - ILA106.50

All Time High

ILA5080.00